Association between drug-eluting stent type and clinical outcomes in patients with chronic kidney disease undergoing percutaneous coronary intervention

Canadian Journal of Cardiology

Volumn 30, Issue 10, 2014, Pages 1170-1176

  Chan, William ^a   Ivanov, Joan ^a   Kotowycz, Mark A ^a   Sibbald, Matthew ^a   McGeoch, Ross ^a   Crooks, Noel ^a   Hatton, Rachael ^a   Ing, Douglas ^a   Daly, Paul ^a   Mackie, Karen ^a   Osten, Mark D ^a   Seidelin, Peter H ^a   Barolet, Alan ^a   Overgaard, Christopher B ^a   Džavík, Vladimír ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DRUG ELUTING STENT; FEMALE; FIRST GENERATION DRUG ELUTING STENT; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; PERCUTANEOUS CORONARY INTERVENTION; REOPERATION; RETROSPECTIVE STUDY; SECOND GENERATION DRUG ELUTING STENT; SURVIVAL RATE; COMORBIDITY; COMPARATIVE STUDY; CORONARY DISEASE; MULTIVARIATE ANALYSIS; PROPENSITY SCORE; REGISTER; RENAL INSUFFICIENCY, CHRONIC;

COMORBIDITY; CORONARY DISEASE; DRUG-ELUTING STENTS; HUMANS; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; REGISTRIES; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 84907964630     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.04.034     Document Type: Article

References (33)

1. Appleby C.E., Ivanov J., Lavi S., et al. The adverse long-term impact of renal impairment in patients undergoing percutaneous coronary intervention in the drug-eluting stent era. Circ Cardiovasc Interv 2009, 2:309-316.
2. Tsai T.T., Messenger J.C., Brennan J.M., et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked cathpci registry-cms claims database. JAm Coll Cardiol 2011, 58:1859-1869.
3. Latif F., Kleiman N.S., Cohen D.J., et al. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv 2009, 2:37-45.
4. Charytan D., Kuntz R.E. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006, 70:2021-2030.
5. Coca S.G., Krumholz H.M., Garg A.X., Parikh C.R. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006, 296:1377-1384.
6. Simsek C., Magro M., Boersma E., et al. Impact of renal insufficiency on safety and efficacy of drug-eluting stents compared to bare-metal stents at 6 years. Catheter Cardiovasc Interv 2012, 80:18-26.
7. Kuchulakanti P.K., Torguson R., Chu W.W., et al. Impact of chronic renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary intervention with sirolimus-eluting stents versus bare metal stents. Am J Cardiol 2006, 97:792-797.
8. Ishio N., Kobayashi Y., Takebayashi H., et al. Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients. Circ J 2007, 71:1525-1529.
9. Garg P., Charytan D.M., Novack L., et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after sirolimus-eluting and bare metal stent implantation (from the SIRIUS trials). Am J Cardiol 2010, 106:1436-1442.
10. Morel O., El Ghannudi S., Jesel L., et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired p2y12 inhibition by clopidogrel. JAm Coll Cardiol 2011, 57:399-408.
11. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293:2126-2130.
12. Best P.J., Lennon R., Ting H.H., et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. JAm Coll Cardiol 2002, 39:1113-1119.
13. Anavekar N.S., Pfeffer M.A. Cardiovascular risk in chronic kidney disease. Kidney Int Suppl 2004, S11-S15.
14. Osten M.D., Ivanov J., Eichhofer J., et al. Impact of renal insufficiency on angiographic, procedural, and in-hospital outcomes following percutaneous coronary intervention. Am J Cardiol 2008, 101:780-785.
15. Hanna E.B., Chen A.Y., Roe M.T., et al. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2011, 4:1002-1008.
16. Stone G.W., Midei M., Newman W., et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation 2009, 119:680-686.
17. Stone G.W., Rizvi A., Newman W., et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. NEngl J Med 2010, 362:1663-1674.
18. Smits P.C., Kedhi E., Royaards K.J., et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial). JAm Coll Cardiol 2011, 58:11-18.
19. Smith S.C., Feldman T.E., Hirshfeld J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006, 113:e166-e286.
20. Austin P.C., Chiu M., Ko D.T., Goeree R., Tu J.V. Chapter 3. Propensity score matching for estimating treatment effect. Analysis of health care data using SAS 2010, SAS Institute, Cary, NC.
21. Parsons LS. Reducing bias in propensity score matched-pair sample using greedy matching techniques. Paper presented at: Proceedings of the twenty-sixth Annual SAS Users Group International Conference. Long Beach, CA: SAS Institute Inc,2001.
22. Lemos P.A., Serruys P.W., van Domburg R.T., et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (Research) Registry. Circulation 2004, 109:190-195.
23. Sarno G., Lagerqvist B., Frobert O., et al. Lower risk of stent thrombosis and restenosis with unrestricted use of "new-generation" drug-eluting stents: a report from The Nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012, 33:606-613.
24. de Waha A., Dibra A., Byrne R.A., et al. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv 2011, 4:371-377.
25. Park D.W., Kim Y.H., Song H.G., et al. Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice: a multicenter, prospective cohort study. Circ Cardiovasc Interv 2012, 5:365-371.
26. Camenzind E., Wijns W., Mauri L., et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012, 380:1396-1405.
27. Nakamura S., Nakamura S., Ogawa H., et al. Comparison of 4 years clinical outcome of stent implantation in renal failure patients with dialysis: comparison with bare metal stents, first generation drug-eluting stents and second generation drug-eluting stents. JAm Coll Cardiol 2011, 57:E1894.
28. Toutouzas K., Patsa C., Synetos A., et al. The impact of new generation drug-eluting stent implantation on patients with chronic kidney disease and a single lesion in the proximal segment of the left anterior descending artery. Hellenic J Cardiol 2011, 52:103-110.
29. Grube E., Chevalier B., Guagliumi G., et al. The SPIRIT V diabetic study: A randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am Heart J 2012, 163:867-875.e861.
30. Kereiakes D.J., Cutlip D.E., Applegate R.J., et al. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system). JAm Coll Cardiol 2010, 56:2084-2089.
31. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85-97.
32. Ota T., Umeda H., Yokota S., et al. Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation. Am Heart J 2009, 158:92-98.
33. Otsuka Y., Ishiwata S., Inada T., et al. Comparison of haemodialysis patients and non-haemodialysis patients with respect to clinical characteristics and 3-year clinical outcomes after sirolimus-eluting stent implantation: insights from the Japan multi-centre post-marketing surveillance registry. Eur Heart J 2011, 32:829-837.